Published in Clin Pharmacol Ther on January 01, 1999
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med (1987) 7.73
A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis (2000) 6.90
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther (2011) 5.44
Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology (1998) 4.52
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2001) 3.85
The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther (2002) 3.71
The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology (2001) 3.60
Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1997) 3.29
Hereditary angioedema: a broad review for clinicians. Arch Intern Med (2001) 2.92
Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut (2000) 2.86
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis (2001) 2.80
Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med (1980) 2.51
Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis. Aliment Pharmacol Ther (2015) 2.25
Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc (1994) 2.23
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut (2005) 2.22
Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther (2010) 2.20
Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut (2009) 2.20
A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Aliment Pharmacol Ther (2014) 2.18
Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology (1999) 2.14
Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside. Lancet (1978) 2.10
Mycophenolate mofetil for Crohn's disease? Lancet (1999) 2.03
Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther (2013) 1.99
Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther (2005) 1.96
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology (1999) 1.84
Misdiagnosis of specific cytomegalovirus infection of the ileoanal pouch as refractory idiopathic chronic pouchitis: report of two cases. Dis Colon Rectum (1999) 1.79
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut (2008) 1.75
Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol (2000) 1.71
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther (2013) 1.69
Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2013) 1.63
Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry. Neurogastroenterol Motil (2009) 1.62
Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc (1996) 1.61
Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology (1999) 1.61
Nonsteroidal anti-inflammatory drug-induced enteropathy: case discussion and review of the literature. Mayo Clin Proc (1995) 1.59
Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med (1984) 1.57
Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther (2014) 1.56
Successful management of Crohn's disease of the ileoanal pouch with infliximab. Gastroenterology (1999) 1.56
Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol (2000) 1.56
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther (2009) 1.54
Cyclosporine therapy for inflammatory bowel disease: definitive answers and remaining questions. Gastroenterology (1995) 1.54
Maintenance of symptomatic remission in patients with Crohn's disease. Mayo Clin Proc (1993) 1.54
MHC Class II alleles in ulcerative colitis-associated colorectal cancer. Gut (2009) 1.53
Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc (1996) 1.47
A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. Gastroenterology (2001) 1.47
Intravenous azathioprine in severe ulcerative colitis: a pilot study. Am J Gastroenterol (2000) 1.46
Epidemiology of inflammatory bowel disease in Asia. Inflamm Bowel Dis (2001) 1.46
Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology (1996) 1.46
Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis (2001) 1.44
Antineutrophil cytoplasmic antibody subtypes in children and adolescents after ileal pouch-anal anastomosis for ulcerative colitis. J Pediatr Gastroenterol Nutr (1998) 1.44
Early measles virus infection is associated with the development of inflammatory bowel disease. Am J Gastroenterol (2000) 1.42
N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia. Lancet (1983) 1.41
Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol (1998) 1.39
Methylphenidate: its pharmacology and uses. Mayo Clin Proc (2000) 1.39
Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem (1999) 1.38
Concurrent inflammatory bowel disease and myelodysplastic syndromes. Inflamm Bowel Dis (1999) 1.36
Relationship between aminoglycoside-induced nephrotoxicity and auditory toxicity. Antimicrob Agents Chemother (1979) 1.33
Risk of colorectal neoplasia in patients with primary sclerosing cholangitis. Gastroenterology (1996) 1.33
Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther (2013) 1.32
Diagnosis and treatment of perianal fistulas in Crohn disease. Ann Intern Med (2001) 1.30
Controlled trial of bowel rest and nutritional support in the management of Crohn's disease. Gut (1988) 1.29
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol (2007) 1.28
Hypoprothrombinemia and platelet dysfunction caused by cephalosporin and oxalactam antibiotics. J Antimicrob Chemother (1983) 1.28
Cigarette smoking and celiac sprue: a case-control study. Am J Gastroenterol (2001) 1.27
Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther (2007) 1.25
Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol (2001) 1.24
Crohn's disease of the esophagus: clinical features and outcomes. Inflamm Bowel Dis (2001) 1.24
Sequential histologic evaluations in collagenous colitis. Correlations with disease behavior and sampling strategy. Dig Dis Sci (1992) 1.19
Drug-grapefruit juice interactions. Mayo Clin Proc (2000) 1.19
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther (2010) 1.18
Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. Am J Gastroenterol (1993) 1.17
Ischemic proctosigmoiditis. Am J Gastroenterol (1996) 1.17
Mechanism of the inhibition of the gamma-carboxylation of glutamic acid by N-methylthiotetrazole-containing antibiotics. Proc Natl Acad Sci U S A (1984) 1.16
Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis (2012) 1.15